1-15 of 15
Alona Muzikansky
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma

Free
Fabio M. Iwamoto, Shyam K. Tanguturi, Lakshmi Nayak, Tony J. Wang, Arati Desai, Robert A. Lustig, Stephen Bagley, Eric T. Wong, Lauren M. Hertan, Christine McCluskey, Julia Hayden, Alona Muzikansky, Shreya Nakhawa, Julia Japo, Connor C. Bossi, Maxime Meylan, Ye Tian, Graham L. Barlow, Paul Speliakos, Georges Ayoub, David M. Meredith, Keith L. Ligon, Daphne Haas-Kogan, Kun Huang, Kai W. Wucherpfennig, Patrick Y. Wen, David A. Reardon
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (2): 316–327.
https://doi.org/10.1158/1078-0432.CCR-24-1629
Published: 17 January 2025
View articletitled, Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma
Open the PDF for Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma in another window
Includes: Supplementary data
Journal Articles

A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors

Available to Purchase
Gregory M. Cote, Bose S. Kochupurakkal, Khanh Do, Andrea Bullock, Michael L. Cheng, Alona Muzikansky, Daniel E. McLoughlin, James M. Cleary, Xin Gao, Aparna Parikh, Jong Chul Park, Colin D. Weekes, Oladapo Yeku, Lee Zou, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (1): 35–44.
https://doi.org/10.1158/1078-0432.CCR-24-1867
Published: 06 January 2025
View articletitled, A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors
Open the PDF for A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma

Available to Purchase
Mary Jane Lim-Fat, J. Bryan Iorgulescu, Rifaquat Rahman, Varun Bhave, Alona Muzikansky, Eleanor Woodward, Sydney Whorral, Marie Allen, Mehdi Touat, Xiaomei Li, Gongwen Xy, Jay Patel, Elizabeth R. Gerstner, Jayashree Kalpathy-Cramer, Gilbert Youssef, Ugonma Chukwueke, J. Ricardo McFaline-Figueroa, Lakshmi Nayak, Eudocia Q. Lee, David A. Reardon, Rameen Beroukhim, Raymond Y. Huang, Wenya Linda Bi, Keith L. Ligon, Patrick Y. Wen
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (7): 1327–1337.
https://doi.org/10.1158/1078-0432.CCR-23-3018
Published: 01 April 2024
View articletitled, Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma
Open the PDF for Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients

Available to Purchase
K. Ina Ly, Leland G. Richardson, Mofei Liu, Alona Muzikansky, Jonathan Cardona, Kevin Lou, Andrew L. Beers, Ken Chang, James M. Brown, Xiaoyue Ma, David A. Reardon, Isabel C. Arrillaga-Romany, Deborah A. Forst, Justin T. Jordan, Eudocia Q. Lee, Jorg Dietrich, Lakshmi Nayak, Patrick Y. Wen, Ugonma Chukwueke, Anita Giobbie-Hurder, Bryan D. Choi, Tracy T. Batchelor, Jayashree Kalpathy-Cramer, William T. Curry, Elizabeth R. Gerstner
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (16): 3017–3025.
https://doi.org/10.1158/1078-0432.CCR-23-0203
Published: 15 August 2023
View articletitled, Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients
Open the PDF for Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients in another window
Includes: Supplementary data
Journal Articles

Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)

Available to Purchase
Erin M. Bertino, Ryan D. Gentzler, Sarah Clifford, Jill Kolesar, Alona Muzikansky, Eric B. Haura, Zofia Piotrowska, D. Ross Camidge, Thomas E. Stinchcombe, Christine Hann, Jyoti Malhotra, Liza C. Villaruz, Cloud P. Paweletz, Christie L. Lau, Lynette Sholl, Naoko Takebe, Jeffrey A. Moscow, Geoffrey I. Shapiro, Pasi A. Jänne, Geoffrey R. Oxnard
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (6): 1604–1611.
https://doi.org/10.1158/1078-0432.CCR-20-4084
Published: 15 March 2021
View articletitled, Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)
Open the PDF for Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903) in another window
Includes: Supplementary data
Journal Articles

Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

Free
Lakshmi Nayak, Annette M. Molinaro, Katherine Peters, Jennifer L. Clarke, Justin T. Jordan, John de Groot, Leia Nghiemphu, Thomas Kaley, Howard Colman, Christine McCluskey, Sarah Gaffey, Timothy R. Smith, David J. Cote, Mariano Severgnini, Jennifer H. Yearley, Qing Zhao, Wendy M. Blumenschein, Dan G. Duda, Alona Muzikansky, Rakesh K. Jain, Patrick Y. Wen, David A. Reardon
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (4): 1048–1057.
https://doi.org/10.1158/1078-0432.CCR-20-2500
Published: 15 February 2021
View articletitled, Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
Open the PDF for Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma in another window
Includes: Supplementary data
Journal Articles

A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma

Free
Patrick Y. Wen, David A. Reardon, Terri S. Armstrong, Surasak Phuphanich, Robert D. Aiken, Joseph C. Landolfi, William T. Curry, Jay-Jiguang Zhu, Michael Glantz, David M. Peereboom, James M. Markert, Renato LaRocca, Donald M. O'Rourke, Karen Fink, Lyndon Kim, Michael Gruber, Glenn J. Lesser, Edward Pan, Santosh Kesari, Alona Muzikansky, Clemencia Pinilla, Radleigh G. Santos, John S. Yu
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (19): 5799–5807.
https://doi.org/10.1158/1078-0432.CCR-19-0261
Published: 01 October 2019
View articletitled, A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma
Open the PDF for A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma in another window
Includes: Supplementary data
Journal Articles

A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma

Free
Lipika Goyal, Hui Zheng, Thomas A. Abrams, Rebecca Miksad, Andrea J. Bullock, Jill N. Allen, Matthew B. Yurgelun, Jeffrey W. Clark, Avinash Kambadakone, Alona Muzikansky, Michelle Knowles, Aralee Galway, Anthony J. Afflitto, Caroline F. Dinicola, Eileen Regan, Tai Hato, Emilie Mamessier, Kohei Shigeta, Rakesh K. Jain, Dan G. Duda, Andrew X. Zhu
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (1): 80–89.
https://doi.org/10.1158/1078-0432.CCR-18-0847
Published: 03 January 2019
View articletitled, A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma
Open the PDF for A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma in another window
Includes: Supplementary data
Journal Articles

Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma

Free
Eudocia Q. Lee, Dan G. Duda, Alona Muzikansky, Elizabeth R. Gerstner, John G. Kuhn, David A. Reardon, Lakshmi Nayak, Andrew D. Norden, Lisa Doherty, Debra LaFrankie, Jennifer Stefanik, Trupti Vardam, Katrina H. Smith, Christine McCluskey, Sarah Gaffey, Tracy T. Batchelor, Rakesh K. Jain, Patrick Y. Wen
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (19): 4643–4649.
https://doi.org/10.1158/1078-0432.CCR-18-1025
Published: 01 October 2018
View articletitled, Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma
Open the PDF for Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma in another window
Journal Articles

Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses

Free
Tilak K. Sundaresan, Lecia V. Sequist, John V. Heymach, Gregory J. Riely, Pasi A. Jänne, Walter H. Koch, James P. Sullivan, Douglas B. Fox, Robert Maher, Alona Muzikansky, Andrew Webb, Hai T. Tran, Uma Giri, Martin Fleisher, Helena A. Yu, Wen Wei, Bruce E. Johnson, Thomas A. Barber, John R. Walsh, Jeffrey A. Engelman, Shannon L. Stott, Ravi Kapur, Shyamala Maheswaran, Mehmet Toner, Daniel A. Haber
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (5): 1103–1110.
https://doi.org/10.1158/1078-0432.CCR-15-1031
Published: 29 February 2016
View articletitled, Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses
Open the PDF for Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses in another window
Includes: Supplementary data
Journal Articles

A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients

Free
Eudocia Q. Lee, Thomas J. Kaley, Dan G. Duda, David Schiff, Andrew B. Lassman, Eric T. Wong, Tom Mikkelsen, Benjamin W. Purow, Alona Muzikansky, Marek Ancukiewicz, Jason T. Huse, Shakti Ramkissoon, Jan Drappatz, Andrew D. Norden, Rameen Beroukhim, Stephanie E. Weiss, Brian M. Alexander, Christine S. McCluskey, Mary Gerard, Katrina H. Smith, Rakesh K. Jain, Tracy T. Batchelor, Keith L. Ligon, Patrick Y. Wen
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (16): 3610–3618.
https://doi.org/10.1158/1078-0432.CCR-14-3220
Published: 13 August 2015
View articletitled, A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients
Open the PDF for A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients in another window
Includes: Supplementary data
Journal Articles

Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study

Free
Andrew X. Zhu, Marek Ancukiewicz, Jeffrey G. Supko, Dushyant V. Sahani, Lawrence S. Blaszkowsky, Jeffrey A. Meyerhardt, Thomas A. Abrams, Nadine Jackson McCleary, Pankaj Bhargava, Alona Muzikansky, Susan Sheehan, Eileen Regan, Eamala Vasudev, Michelle Knowles, Charles S. Fuchs, David P. Ryan, Rakesh K. Jain, Dan G. Duda
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (6): 1557–1566.
https://doi.org/10.1158/1078-0432.CCR-12-3041
Published: 14 March 2013
View articletitled, Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
Open the PDF for Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study in another window
Includes: Supplementary data
Journal Articles

Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults

Free
Santosh Kesari, David Schiff, Jan Drappatz, Debra LaFrankie, Lisa Doherty, Eric A. Macklin, Alona Muzikansky, Sandro Santagata, Keith L. Ligon, Andrew D. Norden, Abigail Ciampa, Joanna Bradshaw, Brenda Levy, Gospova Radakovic, Naren Ramakrishna, Peter M. Black, Patrick Y. Wen
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (1): 330–337.
https://doi.org/10.1158/1078-0432.CCR-08-0888
Published: 31 December 2008
View articletitled, Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults
Open the PDF for Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults in another window
Journal Articles

Prognostic and Pathologic Significance of Quantitative Protein Expression Profiling in Human Gliomas

Free
Arnab Chakravarti, Meaghan A. Delaney, Elizabeth Noll, Peter McL. Black, Jay S. Loeffler, Alona Muzikansky, Nicholas J. Dyson
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (8): 2387–2395.
Published: 01 August 2001
View articletitled, Prognostic and Pathologic Significance of Quantitative Protein Expression Profiling in Human Gliomas
Open the PDF for Prognostic and Pathologic Significance of Quantitative Protein Expression Profiling in Human Gliomas in another window
Journal Articles

A Phase II Trial of the Cyclin-dependent Kinase Inhibitor Flavopiridol in Patients with Previously Untreated Stage IV Non-Small Cell Lung Cancer

Free
Geoffrey I. Shapiro, Jeffrey G. Supko, Angus Patterson, Cathy Lynch, Joan Lucca, Patrick F. Zacarola, Alona Muzikansky, John J. Wright, Thomas J. Lynch, Jr., Barrett J. Rollins
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (6): 1590–1599.
Published: 01 June 2001
View articletitled, A Phase II Trial of the Cyclin-dependent Kinase Inhibitor Flavopiridol in Patients with Previously Untreated Stage IV Non-Small Cell Lung Cancer
Open the PDF for A Phase II Trial of the Cyclin-dependent Kinase Inhibitor Flavopiridol in Patients with Previously Untreated Stage IV Non-Small Cell Lung Cancer in another window